Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
Study Identifier:
ENB-002-08
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: asfotase alfa
Date
Sep 2008 - May 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 36 Months
Requirements Information
Sex
Female & Male
Age
N/A - 36 Months
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: asfotase alfa
Date
Sep 2008 - May 2010
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - 36 Months years
Requirements Information
Protocol Summary
This clinical trial studies the safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP.
Trial Locations
Location
Status
Location
Arkansas Children's Hospital
Little Rock, Arkansas, United States, 72202
Status
N/A
Location
Alfred I. duPont Hospital for Children
Wilmington, Delaware, United States, 19803
Status
N/A
Location
St. John's Hospital
Springfield, Missouri, United States, 65804
Status
N/A
Location
University of Nebraska Medical Center, Munroe-Meyer Institute
Omaha, Nebraska, United States, 68114
Status
N/A
Location
Vanderbilt Children's Hospital
Nashville, Tennessee, United States, 37232
Status
N/A
Location
St. Vincent Hospital
Green Bay, Wisconsin, United States, 54301
Status
N/A